Methylcobalamin: Corrin Structure, Methionine Synthase Chemistry and Cell Trafficking

Methylcobalamin belongs to the corrinoid family: a cobalt ion held in a partially reduced tetrapyrrole ring called corrin, carrying a nucleotide loop that folds back to coordinate the metal from below. The upper coordination site holds a methyl group joined to cobalt through a genuine metal-carbon bond.

Corrin differs from porphyrin in two structural details that matter chemically. One of the four methine bridges is missing, so rings A and D are joined directly, and the macrocycle is more reduced and less symmetric than a porphyrin. That lowered symmetry decouples the spectroscopic signature of the trans-axial ligand from that of the methyl group, a point exploited analytically in the X-ray absorption work described further below. Six amide side chains decorate the periphery, and one of them extends into the aminopropanol-phosphate-ribose arm that terminates in 5,6-dimethylbenzimidazole.

Two coordination states are described throughout the literature. In the base-on form the benzimidazole nitrogen occupies the lower axial position; in the base-off form it swings away and is replaced by water, by a protein-supplied histidine, or by nothing at all. Acid drives the free molecule base-off by protonating the benzimidazole, which is visible as a shift of the ultraviolet-visible maxima from 266, 342 and 522 nm at pH 7.0 to 264, 304 and 462 nm in 0.1 N hydrochloric acid. Mammalian enzymes exploit the same switch deliberately, displacing the intramolecular base with a histidine residue.

Methylcobalamin is the working cofactor of methionine synthase, the cobalamin-dependent enzyme designated MTR in humans and MetH in bacteria. The enzyme moves a methyl group from 5-methyltetrahydrofolate onto homocysteine, producing methionine and tetrahydrofolate, and the cobalt centre serves as the intermediate that carries that methyl group between the two substrates.

The cycle alternates between two oxidation states. Enzyme-bound methylcobalamin transfers its methyl group to the thiolate of homocysteine, leaving cob(I)alamin, a species nucleophilic enough that chemists call it supernucleophilic. Cob(I)alamin then abstracts a methyl group from 5-methyltetrahydrofolate, restoring the methylated Co(III) state. Because Co(I) is easily oxidised, the enzyme drifts into an inactive cob(II)alamin form and must be repaired by reductive methylation using methionine synthase reductase, NADPH and S-adenosylmethionine.

Structural work has caught up with the mechanism only recently. Mendoza and colleagues reported the first full-length structure of a cobalamin-dependent methionine synthase in Nature Communications in 2023, using a thermophilic homologue and capturing cofactor loading in crystallo. Ferreira and colleagues followed in 2026 with cryo-electron microscopy structures of the human enzyme in apo and cobalamin-bound states, showing that the two halves of the apo protein act independently until cofactor binding produces a flexible catalytically competent arrangement, and that methionine synthase reductase engages two distinct sites within the cobalamin-binding half.

Kinetics show how narrow the tolerance is. Guha and Banerjee reported in the Journal of Biological Chemistry in 2025 that the P1173L variant of human MTR retains near-normal specific activity when driven by an artificial reducing system, yet shows a Michaelis constant for S-adenosylmethionine roughly 40-fold higher than wild type and roughly 30-fold lower activity under the physiologically relevant reductase-plus-NADPH system. Pre-steady-state analysis placed electron transfer from the reductase to cob(II)alamin as the rate-limiting step, so the defect lies in reactivation rather than in methyl transfer itself.

Methylcobalamin is not taken up directly by mammalian cells. Circulating cobalamin travels bound to transcobalamin, enters through the receptor CD320, and passes through the lysosome before cytosolic enzymes strip its upper ligand and rebuild the methylated form. Each step in that route has been mapped structurally within the past three years.

CD320 turned out to be more complex than the textbook monomer. Guo and colleagues reported in 2026 that the receptor sits at the surface of HEK293 cells as an oligomer of five homomers cross-linked by disulfide bonds, assembled in the endoplasmic reticulum, requiring the transmembrane domain but neither N- nor O-glycosylation for oligomerisation itself. Deleting the low-density-lipoprotein-receptor-like domains abolished both oligomerisation and surface localisation and cut cobalamin uptake. Earlier work from the same group had shown that O-glycans, rather than N-glycans, control trafficking of the receptor to the surface, with the three N-glycosylation sites Asn126, Asn195 and Asn213 dispensable for that step.

Export from the lysosome depends on a transporter-chaperone pair. Liu and colleagues published cryo-electron microscopy structures in Nature Communications in 2026 of the cobalamin exporter ABCD4 in complex with LMBD1, resolved in lumen-open, substrate-bound and cytosol-open states. LMBD1 contributes nine transmembrane helices and a cytosolic domain, both engaging ABCD4, and disrupting those contacts left the exporter unable to reach lysosomes in cell imaging.

In the cytosol the processing enzyme CblC, encoded by MMACHC, removes the upper axial ligand. Esser and colleagues characterised that reaction in Biochemistry in 2025, showing glutathione-driven demethylation of methylcobalamin that yields aquacobalamin together with a stoichiometric equivalent of S-methylglutathione. Replacing the conserved Cys149 with serine or alanine accelerated the observed demethylation rate while uncoupling electron transfer and raising oxidised glutathione output, indicating that the residue tunes the enzyme toward economy rather than speed. Downstream, the chaperone MMADHC delivers the freed cobalamin to methionine synthase, an interaction confirmed by the 2026 cryo-electron microscopy study.

The cobalt-carbon bond of methylcobalamin is one of only two organometallic linkages known in mammalian biochemistry, the other being the cobalt-adenosyl bond of adenosylcobalamin. Bond strength, photosensitivity and the identity of the trans-axial ligand together decide whether that bond breaks homolytically into radicals or heterolytically into ions.

Gas-phase measurements on the base-off cobinamide analogues place homolytic bond dissociation values at 44.6 plus or minus 0.8 kcal/mol for methylcobinamide against 41.5 plus or minus 1.2 kcal/mol for adenosylcobinamide, the methyl species being the stronger of the pair. Enzymes shift these numbers by remodelling the lower axial position, which is why the trans-axial ligand is studied so closely. Zhao and colleagues applied cobalt K-edge X-ray absorption spectroscopy in 2026 across methylcobalamin, methylcobinamide and the methylated corrinoid iron-sulfur protein of the Wood-Ljungdahl pathway, finding near-identical cobalt-methyl distances yet a systematic rise in pre-edge intensity and a shift to lower transition energy. Their analysis assigned that trend to the trans-axial distance and concluded that the methylated protein retains a weakly bound water rather than being five-coordinate.

Photochemistry provides the second handle. Mukherjee and colleagues reported in Chemical Science in 2026 that anaerobic photolysis of alkylcobalamins in aqueous solution generates Co(I) in nearly quantitative yield, but that adding alkyl halide to that Co(I) does not regenerate the Co(III)-alkyl species quantitatively as its nucleophilicity would predict. A branching pathway intervenes, and both the final cobalt oxidation state and the fate of the organic radical proved solvent-dependent. Computational work published earlier had shown that molecular oxygen redirects methylcobalamin photolysis entirely, with the released methyl radical combining with dioxygen and recombining with the cobalt(II) corrin instead of escaping.

Methylcorrinoid chemistry reaches far beyond methionine synthase. Anaerobic bacteria and archaea run whole metabolisms on methyl-cobalt intermediates, transferring methyl groups from quaternary amines, methoxylated aromatics, halogenated alkanes and carbon monoxide onto corrinoid proteins that are chemically close relatives of methylcobalamin itself.

Picking and colleagues delineated the active site of MtgB, a cobalamin-dependent glycine betaine methyltransferase from Desulfitobacterium hafniense, in the Journal of Biological Chemistry in 2026. Two aromatic residues, Tyr97 and Phe356, engage the quaternary amine through pi-cation contacts while His348 and Arg312 hold the carboxylate, positioning the substrate for nucleophilic attack by the Co(I) centre. Modelling other members of the MttB superfamily placed the quaternary nitrogen of each substrate within an average of 1.8 Å of the others inside the TIM-barrel fold, implying a shared geometry for methyl delivery to cobalt.

Two 2026 papers extended the same logic to different chemistry. Bernhardt and colleagues identified the cdmBCA gene cluster of the acetogen Acetobacterium dehalogenans in Nature Communications as the long-sought corrinoid-dependent chloromethane methyltransferase system, with a crystal structure of CdmB revealing a hydrophobic channel steering haloalkanes toward cobalamin-dependent activation. Bourdin and colleagues characterised glutamine C-methyltransferase in Communications Biology, a cobalamin-dependent radical S-adenosylmethionine enzyme that methylates a glutamine in the active site of methyl-coenzyme M reductase, and showed that hydrogen-atom abstraction and methyl transfer are separate rather than concerted events.

Reliance on cobalamin also creates a vulnerability that shapes microbial communities. Wasson and McRose reported in mBio in 2026 that nitrous oxide inactivates cobalamin-dependent methionine synthase: deleting metE in Pseudomonas aeruginosa, forcing exclusive reliance on the cobalamin-dependent MetH route, sensitised the organism to both exogenous and self-produced nitrous oxide. A substantial fraction of an Arabidopsis thaliana rhizosphere culture collection was found to carry only cobalamin-dependent methionine synthases, and one such isolate was suppressed in co-culture with a nitrous-oxide-producing denitrifier.

Cell-based work published since 2025 has used methylcobalamin availability as an experimental variable rather than a fixed background condition. Cancer cell lines, T lymphocyte lines and brain-specific knockout mice each expose a different consequence of interrupting the methylcobalamin-dependent branch of one-carbon metabolism, and the readouts are metabolic rather than descriptive.

Husseiny and Nilsson addressed a decades-old puzzle in Cancer and Metabolism in 2025. Many cancer cell lines fail to grow when methionine in the medium is replaced by homocysteine, despite carrying an intact methionine synthase gene. Culturing such lines with high cobalamin for extended periods produced revertants able to grow on homocysteine, and metabolic flux analysis showed the parental cells never fully engaging methionine synthase. Expressing a cobalamin-independent methionine synthase restored growth and normalised the ratio of S-adenosylmethionine to S-adenosylhomocysteine, whereas overexpressing the cobalamin-dependent human enzyme did nothing, locating the limitation in cofactor supply rather than in enzyme abundance.

A separate 2026 report placed methylcobalamin in an unrelated role. Wang and colleagues, working in Virologica Sinica, characterised gasdermin-E-dependent pyroptosis triggered by enterovirus A71 in Jurkat and EL-4 T cell lines and in primary mouse CD3-positive T cells, driven through caspase-3 rather than through gasdermin D. Methylcobalamin, applied as a gasdermin E inhibitor, limited the resulting T-cell loss in culture and raised survival in an infected newborn mouse model to 80 percent. The observation is notable because the molecule acts there as a direct protein inhibitor rather than as an enzyme cofactor.

Methylcobalamin is supplied as a dark red crystalline solid that decomposes above 190 °C rather than melting cleanly. Published property data describe it as sparingly soluble in cold water and more soluble in hot, and material is normally kept sealed against moisture in a freezer at or below −20 °C. The corrin ring accounts for the colour: aqueous solutions are visibly red-pink even at low micromolar concentration.

Light is the dominant stability variable, and it is a chemical rather than a nuisance problem. The cobalt-carbon bond absorbs in the visible region and cleaves photolytically, so ordinary bench lighting slowly converts methylcobalamin into cob(II)alamin, aquacobalamin and related species. Published spectroscopic work shows the outcome depends on whether oxygen is present: under anaerobic conditions the cobalt centre can be driven nearly quantitatively to Co(I), while under air the released methyl radical combines with dioxygen and recombines with the cobalt(II) corrin. Standard practice is amber glassware or foil-wrapped vessels, subdued room lighting, and solutions prepared shortly before measurement.

Identity is confirmed spectroscopically before anything else. Ultraviolet-visible scanning in phosphate buffer at pH 7.0 should reproduce maxima near 266, 342 and 522 nm, and acidifying the same sample to 0.1 N hydrochloric acid should shift them to approximately 264, 304 and 462 nm as the benzimidazole protonates and the molecule converts to the base-off form. That pH-dependent shift distinguishes an alkylcobalamin from cyanocobalamin, whose spectrum is dominated by a band near 361 nm. Mass spectrometry against a monoisotopic mass of 1343.5878 Da and reversed-phase HPLC purity on the lot certificate of analysis complete the identity package.

Two contamination questions recur in method sections. First, photodegradation products are themselves cobalamins and remain red, so visual inspection tells nothing; chromatography is required. Second, cyanide traces during synthesis or workup convert alkylcobalamins to cyanocobalamin, which is why suppliers report the four cobalamin forms separately rather than as total corrinoid.

This material is offered for laboratory research use only. It is not a drug, not a food, and not intended for human or veterinary use.